NASDAQ:ALLK Allakos (ALLK) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free ALLK Stock Alerts $1.02 0.00 (0.00%) (As of 10:16 AM ET) Add Compare Share Share Today's Range$0.98▼$1.0350-Day Range$1.05▼$1.6452-Week Range$0.98▼$5.64Volume136,087 shsAverage Volume1.25 million shsMarket Capitalization$89.63 millionP/E RatioN/ADividend YieldN/APrice Target$1.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Allakos alerts: Email Address Allakos MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside79.7% Upside$1.83 Price TargetShort InterestHealthy6.33% of Shares Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.16) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.48 out of 5 starsMedical Sector151st out of 907 stocksPharmaceutical Preparations Industry55th out of 422 stocks 3.1 Analyst's Opinion Consensus RatingAllakos has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageAllakos has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.33% of the outstanding shares of Allakos have been sold short.Short Interest Ratio / Days to CoverAllakos has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allakos has recently decreased by 0.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAllakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Allakos is -0.86. Previous Next 2.7 News and Social Media Coverage News SentimentAllakos has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Allakos this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Allakos to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have not sold or bought any company stock.Percentage Held by Insiders28.07% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Allakos are expected to grow in the coming year, from ($1.16) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Allakos Stock (NASDAQ:ALLK)Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Read More ALLK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLK Stock News HeadlinesApril 24, 2024 | markets.businessinsider.comMarket Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical DevelopmentsApril 9, 2024 | investorplace.com3 Biotech Stocks to Dump Before They Go to ZeroApril 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 19, 2024 | markets.businessinsider.comHold Rating on Allakos Amidst Cautious Optimism for AK006 ProgramMarch 16, 2024 | finance.yahoo.comAllakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4March 15, 2024 | markets.businessinsider.comHold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 DevelopmentsMarch 15, 2024 | markets.businessinsider.comBuy Rating Maintained for Century Therapeutics with Increased Price Target Amid Promising Trials and Strong FinancialsMarch 15, 2024 | markets.businessinsider.comTD Cowen Remains a Hold on Allakos (ALLK)April 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 14, 2024 | investorplace.comALLK Stock Earnings: Allakos Misses EPS for Q4 2023March 14, 2024 | globenewswire.comAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | finanznachrichten.deAllakos Inc.: Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024February 26, 2024 | globenewswire.comAllakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024February 17, 2024 | finance.yahoo.comALLK Sep 2024 2.000 callFebruary 17, 2024 | finance.yahoo.comALLK Sep 2024 2.500 callFebruary 17, 2024 | finance.yahoo.comALLK Mar 2024 1.500 callFebruary 12, 2024 | finanznachrichten.deAllakos Inc.: Allakos Announces Publication Highlighting AK006 Mast Cell InhibitionFebruary 12, 2024 | finance.yahoo.comAllakos Announces Publication Highlighting AK006 Mast Cell InhibitionJanuary 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLKJanuary 18, 2024 | finance.yahoo.comHere's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 WeeksJanuary 17, 2024 | realmoney.thestreet.comAllakos price target lowered by 50c at Barclays, here's whyJanuary 17, 2024 | msn.comAllakos extends losses as analysts downgrade on Phase 2 setbackJanuary 16, 2024 | realmoney.thestreet.comAllakos just downgraded at Cantor Fitzgerald, here's whyJanuary 16, 2024 | realmoney.thestreet.comAllakos just downgraded at LifeSci Capital, here's whyJanuary 16, 2024 | finance.yahoo.comIs Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?January 16, 2024 | investorplace.comWhy Is Allakos (ALLK) Stock Down 57% Today?January 16, 2024 | marketwatch.comAllakos to Cut Workforce by Half Amid Results from Lirentelimab TrialsSee More Headlines Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALLK CUSIPN/A CIK1564824 Webwww.allakos.com Phone(650) 597-5002FaxN/AEmployees131Year FoundedN/APrice Target and Rating Average Stock Price Target$1.83 High Stock Price Target$3.00 Low Stock Price Target$1.00 Potential Upside/Downside+79.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.23% Return on Assets-62.03% Debt Debt-to-Equity RatioN/A Current Ratio4.92 Quick Ratio4.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.93 per share Price / Book0.53Miscellaneous Outstanding Shares87,870,000Free Float63,208,000Market Cap$89.63 million OptionableOptionable Beta0.82 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Robert Alexander Ph.D. (Age 54)CEO & Director Comp: $1.46MDr. Adam L. Tomasi Ph.D. (Age 54)President Comp: $1.11MMr. Baird Radford III (Age 54)Chief Financial Officer Comp: $708.26kMs. Mary Cromwell Ph.D.Chief Technical OfficerDr. Chin Lee M.D. (Age 53)M.P.H., Chief Medical Officer Mr. Alan ChangDirector of Medical Affairs & Data AnalyticsMore ExecutivesKey CompetitorsDiaMedica TherapeuticsNASDAQ:DMACSELLAS Life Sciences GroupNASDAQ:SLSPMV PharmaceuticalsNASDAQ:PMVPProPhase LabsNASDAQ:PRPHAbeona TherapeuticsNASDAQ:ABEOView All CompetitorsInstitutional OwnershipSectoral Asset Management Inc.Sold 17,751 shares on 2/14/2024Ownership: 0.860%Pennant Investors LPBought 186,100 shares on 2/14/2024Ownership: 0.213%Aristides Capital LLCBought 55,900 shares on 2/13/2024Ownership: 0.064%Simplex Trading LLCBought 7,000 shares on 2/2/2024Ownership: 0.000%Vontobel Holding Ltd.Sold 17,751 shares on 1/30/2024Ownership: 0.860%View All Institutional Transactions ALLK Stock Analysis - Frequently Asked Questions Should I buy or sell Allakos stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares. View ALLK analyst ratings or view top-rated stocks. What is Allakos' stock price target for 2024? 5 Wall Street research analysts have issued twelve-month target prices for Allakos' shares. Their ALLK share price targets range from $1.00 to $3.00. On average, they expect the company's share price to reach $1.83 in the next twelve months. This suggests a possible upside of 79.7% from the stock's current price. View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts. How have ALLK shares performed in 2024? Allakos' stock was trading at $2.73 at the beginning of the year. Since then, ALLK shares have decreased by 62.6% and is now trading at $1.02. View the best growth stocks for 2024 here. When is Allakos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ALLK earnings forecast. How were Allakos' earnings last quarter? Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings data on Thursday, March, 14th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.18. What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS). When did Allakos IPO? Allakos (ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager. How do I buy shares of Allakos? Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALLK) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
